Welcome to our dedicated page for Protara Therapeutics news (Ticker: TARA), a resource for investors and traders seeking the latest updates and insights on Protara Therapeutics stock.
Protara Therapeutics, Inc. (Nasdaq: TARA) is a clinical-stage biotechnology company developing therapies for cancer and rare diseases, and its news flow reflects progress across its investigational programs. Company announcements frequently highlight updates on TARA-002, an investigational cell-based therapy in development for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs), as well as on IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients on long-term parenteral support.
Investors following TARA news can expect detailed coverage of clinical trial milestones, including interim data from the Phase 2 ADVANCED-2 trial in NMIBC and the Phase 2 STARBORN-1 trial in pediatric LMs. Recent press releases have discussed complete response rates, safety and tolerability findings, and regulatory feedback from the U.S. Food and Drug Administration (FDA) on potential registrational paths for TARA-002 in both BCG-unresponsive and BCG-naïve NMIBC populations.
News items also report on regulatory designations and programs, such as Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations for TARA-002 in LMs, and Fast Track and Orphan Drug Designations for IV Choline Chloride in patients on long-term parenteral nutrition. In addition, Protara’s releases describe participation of TARA-002 in the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program.
Another key theme in TARA news is capital markets activity, including underwritten public offerings of common stock under the company’s shelf registration statement on Form S-3, with proceeds directed toward the clinical development of TARA-002 and other programs. Corporate updates may reference conference presentations, such as appearances at healthcare conferences, and scheduled webcasts to review new clinical data.
By monitoring this news page, readers can follow Protara’s disclosed clinical data updates, regulatory interactions, financing events, and other material developments that the company reports through press releases and related communications.
Protara Therapeutics (Nasdaq: TARA) announced plans for an additional clinical study to support their Biologics License Application for TARA-002, targeting Lymphatic Malformations (LMs). Based on FDA feedback, the company will conduct large-scale GMP manufacturing comparability in late 2021 and initiate a pediatric clinical study pending alignment with the FDA. TARA-002 is derived from the same cell bank as OK-432, an approved treatment in Japan and Taiwan. Protara aims to deliver the first FDA-approved drug for LMs.
Protara Therapeutics (Nasdaq: TARA) has granted inducement non-qualified stock options for 120,000 shares to Dr. Martín Sebastian Olivo, the new Chief Medical Officer. The options have an exercise price of $15.30 per share, aligning with Protara's closing price as of April 19, 2021. Vesting occurs over four years, with 25% vesting after one year and the remainder vesting monthly. This award, approved by the Compensation Committee, aligns with NASDAQ Listing Rule 5635(c)(4). Protara is focused on developing therapies for cancer and rare diseases.
Protara Therapeutics, Inc. (Nasdaq: TARA) announced the immediate appointment of Dr. Martín Sebastian Olivo as Chief Medical Officer. With over 15 years in oncology research and global drug development, Dr. Olivo previously led clinical development for Gilead Sciences' breast cancer program. His expertise is expected to significantly impact Protara's lead product, TARA-002, for treating non-muscle invasive bladder cancer and lymphatic malformations. Dr. Olivo's experience is anticipated to enhance the company's strategic objectives in developing transformative therapies for cancer and rare diseases.
Protara Therapeutics (Nasdaq: TARA) announced significant advancements in its clinical pipeline, particularly for TARA-002 targeting non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Phase 1 study for NMIBC is expected to begin by year-end 2021, with cash reserves of $169M as of December 31, 2020. R&D expenses surged to $12M in 2020, reflecting growth in clinical programs. However, Protara reported a net loss of $34M, or $4.70 per share, for the year, compared to a $7.8M loss in 2019. The company remains optimistic about its future trajectory.
Protara Therapeutics, Inc. (Nasdaq: TARA) announced participation in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 10:00am ET. The event will be held virtually, and a live audio webcast will be accessible on the company's website. Protara focuses on developing transformative therapies for cancer and rare diseases, with lead programs including TARA-002 for non-muscle invasive bladder cancer and IV Choline Chloride for intestinal failure-associated liver disease.
Protara Therapeutics (Nasdaq: TARA) has announced its participation in two virtual investor conferences. The first is the Guggenheim Healthcare Talks 2021 Oncology Days, scheduled for February 11, 2021, at 9:30 AM ET. The second event is the Cowen 41st Annual Health Care Conference on March 3, 2021, at 1:20 PM ET. Both presentations will be accessible via the Events and Presentations section of Protara's website and archived for 90 days. Protara focuses on innovative therapies for cancer and rare diseases, notably TARA-002 for bladder cancer and IV Choline Chloride for liver disease.
Protara Therapeutics (Nasdaq: TARA) has promoted Jacqueline Zummo, Ph.D., MPH, MBA, from Senior Vice President to Chief Scientific Operations Officer. As a co-founder, Zummo has significantly contributed to the company's advancements, including its lead program TARA-002 for treating non-muscle invasive bladder cancer. With over 15 years of experience in the biopharmaceutical sector, Zummo is expected to drive the growth of Protara's strategies and enhance patient care. The company remains committed to addressing unmet needs in cancer and rare diseases.
Protara Therapeutics, Inc. (Nasdaq: TARA) announced the grant of inducement non-qualified stock options totaling 41,500 shares to two new employees. The options have an exercise price of $22.45, which reflects the company's closing trading price on December 1, 2020, the grant date. Vested shares will occur over four years, with an initial 25% vesting on the one-year anniversary of each employee's start date, followed by monthly vesting. This award was approved by the Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4).
Protara Therapeutics, Inc. (Nasdaq: TARA) has announced participation in two upcoming virtual investor conferences in December 2020. The events include the Piper Sandler 32nd Annual Virtual Healthcare Conference and the Evercore ISI 3rd Annual HealthCONx Virtual Conference, where Protara will present on December 3, 2020, at 12:10 PM ET. A live webcast of the Evercore presentation will be available on the company's website, and a replay of the Piper fireside chat is currently accessible. Protara is focused on transformative therapies for cancer and rare diseases.
Protara Therapeutics (TARA) reported third-quarter 2020 results, highlighting a strong cash position of $166M as of September 30, and a net loss of $8M, compared to $2.4M in Q3 2019. The company confirmed initial comparability between TARA-002 and OK-432, with plans to complete GMP batch runs by mid-2021. Protara is set to initiate a Phase 1 trial for TARA-002 in non-muscle invasive bladder cancer in 2021 and has requested an FDA meeting to discuss the regulatory path for TARA-002 in lymphatic malformations. R&D expenses surged to $2.8M, with general and administrative costs reaching $5.3M.
FAQ
What is the current stock price of Protara Therapeutics (TARA)?
What is the market cap of Protara Therapeutics (TARA)?
